Sierra Oncology SRRA 深 沪
已收盘 07-01 16:00:00 美东时间
54.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 54.99
- 总市值 134.28万
- 52周最高 55.19
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.91
- 委 比 0.00%
- 总股本 2.44万
- 历史最高 163.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.545
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics announced several key leadership appointments to strengthen its executive team. Kevin Norrett was appointed Chief Business Officer, Charles Carter promoted to Chief Financial Officer, Eliseo Salinas joined as Executive R&D Advisor, and Victoria Fort became Chief Strategy Officer. These changes aim to support the company's growth and strategic initiatives in developing innovative treatments for brain disorders.
07-08 11:00
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics, Inc. announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy to advance its PROBODY® pipeline, including the lead program Varseta-M, toward potential commercialization. With over 25 years of experience in regulatory affairs, Dr. Gokhale joins CytomX as it prepares for key regulatory interactions, particularly for Va...
05-18 12:00
Sierra Oncology's Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting On June 7, 10:33 a.m.
Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the
2022-05-27 05:11
Recap: Sierra Oncology Q1 Earnings
Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
2022-05-07 00:00
塞拉肿瘤学第一季度每股收益为1.33美元，高于上年同期的1.46美元
Sierra Oncology (NASDAQ:SRRA) reported quarterly losses of $(1.33) per share. T...
2022-05-06 19:59
Sierra Oncology Q1 EPS $(1.33) Up From $(1.46) YoY
Sierra Oncology (NASDAQ:SRRA) reported quarterly losses of $(1.33) per share. This is a 8.9 percent increase over losses of $(1.46) per share from the same period last year.
2022-05-06 19:07
葛兰素史克Q1业绩爆表 即将分拆消费者保健业务上市
英国制药公司葛兰素史克（GSK.US）于4月27日公布了第一季度业绩，超出分析师预期。该公司一季度营业额增长32%，至97.8亿英镑（123亿美元），超出市...
2022-04-27 16:08
【医疗健康周报】第15周：昂利康以不超过5.6亿元购买“科瑞生物”61%股份，肿瘤靶向药物研发商“Sierra Oncology”以19亿美元被并购
（本文为钛媒体Pro（专业版）用户专享） 「钛媒体Pro周报」通过钛媒体TMTBase全球一级市场数据库，汇总国内外一周投融资事件和热点，旨在让投资人与创业者...
2022-04-19 16:10
